

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Zanubrutinib for treating chronic lymphocytic leukaemia [ID5078]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

The company noted that chronic lymphocytic leukaemia is common in older adults.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Issues relating to disease prevalence cannot usually be addressed by technology appraisals. The committee will consider whether its recommendations make access to treatment more difficult for groups with protected characteristics such as age.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes needed.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No additional stakeholders identified.

Approved by Associate Director (name): Ross Dent

Date: 25/10/2022